mAb showed stronger anti-tumor effect in HFD mouse than that in ND mouse (57.2% and 26.6%, respectively). Metabolomic analysis using HFD and ND mouse serum detected 210 metabolites and The Human Metabolome Database provided comprehensive information of 83 metabolites. Principal component analysis and cluster analysis using these metabolites showed obviously different metabolic properties between ND and HFD mouse. Partial Least Squares-Discriminant Analysis showed significantly high score of lipid metabolites in HFD mouse including a-Tocopherol and cholesterol.

**Conclusions** Metabolomics showed the activation of lipid metabolism in HFD mouse and suggested that LSR contributed tumor growth via lipid metabolism.

**EP284/#1118 DISTRIBUTION OF HOMOLOGOUS RECOMBINATION DEFICIENCY AND BRCA MUTATIONS DETECTED BY HRD-ONE TEST AMONG BRAZILIAN PATIENTS WITH NEWLY DIAGNOSED EPITHELIAL OVARIAN, FOLLIANPHP TUBE, OR PERITONEAL CANCER**

Mariana Scaranti*, Guilherme Lopes Yamamoto, Rodrigo Guarischi Sousa, Ana Carolina J Paniza, Fernanda Milan, Cristovam Scapulatempo-Neto. Hospital 9 de Julho/DASA, Centro De Oncologia, São Paulo, Brazil; Gene One/DASA, Patologia, São Paulo, Brazil

**Objectives** The addition of a poly(ADP-ribose) polymerase (PARP) inhibitor as maintenance therapy led to a significant progression-free survival benefit in patients (pts) with newly diagnosed advanced ovarian cancer who were homologous recombination deficiency (HRD) positive detected by Myriad's myChoice which is economically inaccessible for a significant fraction of the Brazilian population. We updated the analysis of the distribution of HRD and tumor (t) BRCAm in Brazilian pts using the HRD-One test that detects not only sequence variants in genes involved in homologous recombination repair (HRR) but also the genomic scars due to HRD.

**Methods** The accuracy of the HRD-One score was established both by correlation with Myriad’s myChoice score and an internal validation considering that most of the samples that carry a pathogenic variant in BRCA1 or BRCA2 should have HRD. We then tested stage III and IV HGSOc and high-grade endometrioid ovarian cancer pts’ tumor samples with HRD-One test.

**Results** Of the 616 pts, 304(49%) had HRD positive tumors, 277(45%) were HRD negative, and 35(6%) had inconclusive results. 128 pts had tBRCAm, 127(99%) of them had a pathogenic BRCA1 or BRCA2 mutation. 277(45%) were HRD negative, and 35(6%) had inconclusive results. 128 pts had tBRCAm, 127(99%) of them had a pathogenic BRCA1 or BRCA2 mutation.

**Conclusions** Interestingly, we found the dynamic monitoring of circulating TCR repertoire diversity has predictive value on the benefit of PARP inhibitor maintenance therapy in high-grade serous ovarian cancer.

**EP286/#91 EXPRESSION OF CD44+/CD24-, RAD6 AND DDB2 IN CHEMORESISTANCE OVARIAN CANCER**

Unedo Sihombing*, Andrijono Andrijono, Dzicky Fuady, Universitas Indonesia, Obstetrics Gynecology, Central Jakarta, Indonesia

**Objectives** Ovarian cancer is one of the deadliest women cancers around the world with many cases of chemoresistance after cytoreductive surgery and platinum-based chemotherapy. The overexpression of Cancer Stem Cells (CSCs) CD44+/CD24+, RAD6, and underexpression of DDB2 are believed to be associated with chemoresistance. We aimed to analyze the expression of CD44+/CD24+, RAD6 and DDB2 in chemoresistance ovarian cancer tissue and patients’ blood circulation.

**Methods** This study was conducted with an ambispective cohort of 32 people in each group with a total of two groups at the Obstetrics-gynecology and pathology clinic, pathology anatomy department of Cipto Mangunkusumo, Tarakan, Dharmais, and Fatmawati Hospital. All suspected ovarian cancer patients underwent cytoreductive surgery and histopathological examination. Chemotherapy was given for...